Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Argenx SE

Key Facts as at 30.09.2025

Company locationNetherlands 
Size in % of securities14.10%
Size of stake in company0.90%
Market capitalizationUSD 44.4 bn

Sector

Autoimmune diseases

Main candidate

Vyvgart and Vyvgart Hytrulo 

Main indications

Myasthenia gravis

About the company

Argenx is a biotechnology company focused on discovery and development of targeted antibodies through its multiple antibody technology platform. The company is headquartered in Belgium with operations in US and Japan. The company´s lead product Vyvgart (also known as Efgartimod) is marketed for treating generalized Myasthenia gravis. Efgartigimod has the potential to address multiple autoimmune diseases driven by pathological immunoglobulin G. Argenx has several other product candidates in clinical development and can be considered an antibody platform company targeting novel scientific pathways in disease areas with high unmet medical needs.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.